Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders - 2If everyone on Earth sat in the ocean at once, how much would sea level rise?
- 3Home Mechanization Frameworks for Brilliant Residing
- 4Tens of thousands protest as far-right AfD forms new youth group
- 5Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- How Mars' ancient lakes grew shields of ice to stay warm as the Red Planet froze
- Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- How to watch the 2025 Macy's Thanksgiving Day Parade for free
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- Mojtaba Khamenei unconscious in Qom, not actually running Iran
- Bahrain cracks down on dissent as war grinds on
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- 'The Boys' Season 5 premiere: How to watch for less, what to know about the final series and more
- US EPA will reassess safety of herbicide paraquat, says its chief
